Scarica l'app Stockscreener
2.44
3.17%
-0.08
Dopo l'orario di chiusura:
2.63
0.19
+7.79%
Genelux Corp Borsa (GNLX) Ultime notizie
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Equities Analysts Offer Predictions for Genelux Q3 Earnings - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst - TipRanks
Genelux (NASDAQ:GNLX) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer - Quiver Quantitative
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - Yahoo Finance
Genelux (NASDAQ:GNLX) Issues Earnings Results - MarketBeat
Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway - Stock Titan
GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary - TradingView
Genelux Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insiders Sold Genelux At US$3.34, Meanwhile Stock Sits Near US$2.51 - Sahm
Genelux Corp expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Genelux (GNLX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Genelux Corp (GNLX) Balance Sheet - TradingKey
Genelux Corp (GNLX) Cash Flow - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Income Statement - TradingKey
GNLX|Genelux Corp|Price:2.890|Chg%:-0.070 - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux (NASDAQ:GNLX) Shares Down 2.4%Should You Sell? - marketbeat.com
Insider Shake-Up at Genelux Corp Sparks Investor Attention - TipRanks
GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - The Manila Times
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX) - TradingView
Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genelux Corporation 8-K Filing: Company Details, Nasdaq Listing, and Emerging Growth Status (June 2026) - Minichart
Genelux elects director and ratifies auditor at annual shareholder meeting - Investing.com
Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com - Investing.com Nigeria
Form 8K Genelux Corp For: 22 June By Investing.com - Investing.com South Africa
Genelux (GNLX) 2026 meeting backs director John Smither and auditor - Stock Titan
Genelux (GNLX) director receives RSU and stock option grants - Stock Titan
Genelux (GNLX) director receives RSUs and stock options in new grant - Stock Titan
GENELUX (GNLX) CFO receives 278,906 restricted stock units as equity grant - Stock Titan
Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen - Stock Titan
GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan - Stock Titan
GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants - Stock Titan
Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan - Stock Titan
GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant - Stock Titan
GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards - Stock Titan
Genelux Corp (GNLX) Institutional Confidence - TradingKey
Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GNLX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D FocusRevenue Warning Signal - po-news-eg.net
Genelux Corporation (GNLX) Shows Uptick: Testing Key Resistance at $3.13Float Adjusted Cap - dars.gov.et
Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com - Investing.com India
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):